Age-related macular degeneration (AMD) is a leading cause of visual impairment in the United States. Although no therapies are approved to treat the dry form of the disease, the standard of care for wet AMD is vascular endothelial growth factor (VEGF) inhibitors, namely Genentech’s Lucentis, approved for wet AMD; Genentech’s Avastin, approved for cancer but commonly compounded and used off-label for wet AMD; and, most recently, Regeneron’s Eylea. Eylea has experienced rapid and continued uptake due to its favorable attributes. Ahead of the expected entry of new VEGF inhibitors brolucizumab (Novartis) and abicipar pegol (Allergan) to the U.S. wet AMD therapy market, it is essential to understand the current state of the wet AMD market from the perspective of U.S. retinal specialists/ophthalmologists, including their perceptions related to the current anti-VEGF agents for wet AMD.
- What is the relative AMD patient load by disease type (dry versus wet) and disease characteristics? What differences in prescribing behavior exist based upon disease type?
- What patient shares do Avastin, Eylea, and Lucentis capture in wet AMD? How do ophthalmologists/retinal specialists anticipate treating their wet AMD patients one year from now?
- Have physicians’ treatment patterns for their wet AMD patients changed in the past year, and, if so, what factors have driven these changes?
- What are the most influential factors driving ophthalmologists/retinal specialists to administer the current VEGF inhibitors to their wet AMD patients?
- What are the main obstacles to physicians administering Avastin, Eylea, and Lucentis to more of their wet AMD patients?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.
Markets covered: United States
Primary research: Survey of 99 ophthalmologists/retinal specialists in the United States.
Key companies: Genentech, Regeneron, Valeant Pharmaceuticals
Key drugs: Avastin, Eylea, Lucentis, Macugen, Visudyne
Key insights provided:
- Factors influencing disease management and treatment decisions.
- Drivers of and constraints to treatment selection.
- Physician-reported treatment practices and brand-level patient shares.
- Rationale for changes in treatment approach.
- Physician insight on persistency and compliance.
- Physician-reported recent/anticipated changes in brand use or treatment approach.
- Dry And Wet Age-Related Macular Degeneration - Current Treatment - Detailed Expanded Analysis - Physician Insights (US)
Author(s): Emma McFadden, PhD
Emma McFadden, Ph.D., is a Director within the Central Nervous System/Ophthalmology disorders group. Her main focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored research across a number of other indications, including multiple sclerosis and epilepsy.
Prior to joining Decision Resources Group, Emma earned a B.A. in neuroscience and a Ph.D. in biochemistry from Trinity College Dublin.